Patents by Inventor Georges Romey

Georges Romey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for the identification of anesthetics
    Patent number: 7112403
    Abstract: Human and mouse TREK-1 potassium transport proteins are disclosed as well a method for using potassium transport proteins for identifying substances having anesthetic properties, such as producing a safe, reversible state of unconsciousness with concurrent amnesia and analgesia in a mammal upon inhalation, in a method comprising (a) contacting the test substance with a mammalian potassium transport protein, wherein said potassium transport protein exhibits outward-going potassium rectification; and (b) determining the potassium transport activity of the potassium transport protein, wherein an activation of potassium transport is indicative of the test substance having anesthetic properties.
    Type: Grant
    Filed: February 11, 2000
    Date of Patent: September 26, 2006
    Assignees: Centre National de la Recherche Scientifique, CNRS and Fabrice Duprat
    Inventors: Amanda J. Patel, Eric Honore, Florian Lesage, Georges Romey, Michel Lazdunski, Michel Fink, Fabrice Duprat, Francois Maingret
  • Isolated TWIK-1 potassium channel proteins
    Patent number: 7067625
    Abstract: This invention relates to the cloning of a member of a new potassium channel named TWIK-1. More specifically, it relates to an isolated and purified nucleic acid molecule coding for a protein constituting a potassium channel exhibiting the proper-ties and structure of the TWIK-1 type channel, as well as the protein coded by this nucleic acid molecule. The invention also relates to the use of this nucleic acid molecule to transform cells, and the use of these cells expressing the potassium channels exhibiting the properties and structure of the TWIK-1 type channel for the screening of drugs.
    Type: Grant
    Filed: January 11, 2000
    Date of Patent: June 27, 2006
    Inventors: Florian Lesage, Eric Guillemare, Michel Fink, Fabrice Duprat, Michel Lazdunski, Georges Romey, Jacques Barhanin
  • Human TREK2, a stretch- and arachidonic acid-sensitive K+ channel activated by inhalational anesthetics and niluzole
    Patent number: 6962976
    Abstract: This invention relates to a protein including a mammalian K+ channel with two pore domains, designated TREK2, that produces currents whose current-voltage relationship is weakly inward rectifying in high symmetrical K+ conditions. This invention further relates to the isolation and characterization of such protein, as well as a method using TREK2 to identify bioactive compounds having anesthetic properties.
    Type: Grant
    Filed: June 27, 2001
    Date of Patent: November 8, 2005
    Assignee: Centre National de la Recherche Scientifique-CNRS
    Inventors: Michel Lazdunski, Florian Lesage, Georges Romey
  • Human TREK2, a stretch- and arachidonic acid-sensitive K+ channel activated by inhalational anesthetics and riluzole
    Publication number: 20040101833
    Abstract: This invention relates to a protein including a mammalian K+ channel with two pore domains, designated TREK2, that produces currents whose current-voltage relationship is weakly inward rectifying in high symmetrical K+ conditions. This invention further relates to the isolation and characterization of such protein, as well as a method using TREK2 to identify bioactive compounds having anesthetic properties.
    Type: Application
    Filed: June 27, 2001
    Publication date: May 27, 2004
    Inventors: Michel Lazdunski, Florian Lesage, Georges Romey
  • Family of mammalian potassium channels, their cloning and their use especially for the screening of drugs
    Patent number: 6013470
    Abstract: The present invention relates to the cloning of a member of a new potassium channel named TWIK-1. More specifically, it relates to an isolated and purified nucleic acid molecule coding for a protein constituting a potassium channel exhibiting the properties and structure of the TWIK-1 type channel, as well as the protein coded by this nucleic acid molecule.The invention also relates to the use of this nucleic acid molecule to transform cells, and the use of these cells expressing the potassium channels exhibiting the properties and structure of the TWIK-1 type channel for the screening of drugs.
    Type: Grant
    Filed: November 15, 1996
    Date of Patent: January 11, 2000
    Assignee: Centre National de la Recherche Scientifique-CNRS
    Inventors: Florian Lesage, Eric Guillemare, Michel Fink, Fabrice Duprat, Michel Lazdunski, Georges Romey, Jacques Barhanin